Abstract 1807: The discovery and preclinical characterization of the MTA cooperative PRMT5 inhibitor AM-9747

蛋白质精氨酸甲基转移酶5 基因敲除 甲基转移酶 化学 生物化学 合作性 合作约束 癌症研究 分子生物学 基因 生物 甲基化
作者
Brian Belmontes,Antonia Policheni,Siyuan Liu,Katherine Slemmons,Jodi Moriguchi,Huilin Ma,Daniel Aiello,Yajing Yang,Mikkel Vestergaard,Sanne Cowland,Jan M. Anderson,Ian Sarvary,Nuria Tamayo,Liping H. Pettus,Susmith Mukund,Leszek Pope,Jennifer R. Allen,Sanne Glad,Matthew P. Bourbeau,Paul E. Hughes
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:82 (12_Supplement): 1807-1807 被引量:3
标识
DOI:10.1158/1538-7445.am2022-1807
摘要

Abstract Homozygous deletion of the tumor suppressor gene CDKN2A and the neighboring MTAP gene located at chr9p21 occurs in 10-15% of human cancers. Deletion of MTAP, an enzyme in methionine and adenine salvage pathways, results in accumulation of its substrate MTA, which is structurally similar to SAM, the substrate methyl donor for the type II methyltransferase PRMT5. In MTAP deleted cells, MTA competes with SAM for binding to PRMT5, placing PRMT5 in a partially inhibited or hypormorphic state. Multiple studies using shRNAi knockdown have shown that tumor cell lines harboring MTAP deletions are vulnerable to PRMT5 inhibition. PRMT5 inhibitors that have advanced to clinical studies do not selectively target the MTA-bound form of PRMT5, and the preclinical activity of these molecules is not enriched in MTAP-deleted tumor cells lines. Moreover, the therapeutic window of these molecules is narrow, presumably due to the inhibition of PRMT5 in normal cells. We set out to identify PRMT5 inhibitors that bind cooperatively with MTA, with the goal of selectively targeting PRMT5 in MTAP-deleted tumors. A DNA encoded library screen was conducted to identify small molecules that preferentially bind to PRMT5 in the presence of MTA. The subsequent optimization of screening hits to improve potency, MTA-cooperativity, and pharmacokinetic properties led to the identification of AM-9747. The nature of the MTA cooperativity of AM-9747 was interrogated by multiple biophysical methods and structural biology experiments. Following treatment with AM-9747, the levels of SDMA marks were lower in HCT116 MTAP-deleted cells (IC50 = 0.0002 μM) compared to HCT116 MTAP-WT cells (IC50 = 0.050 μM). AM-9747 selectively inhibited the proliferation of HCT116 MTAP-deleted cells (IC50 = 0.027 μM) compared to HCT116 MTAP-WT cells (IC50 = 0.63 μM). The profiling of AM-9747 in an expanded panel of tumor cell lines demonstrated that AM-9747 inhibited the proliferation of most MTAP-deleted cells, with minimal effects on MTAP-WT cells. In vitro mechanism of action studies demonstrated that treatment with AM-9747 induces DNA damage, as illustrated by increased phosphorylation of H2AX, and an arrest in the G2/M phase of the cell cycle in MTAP-deleted cells. In vivo, oral administration of AM-9747 selectively inhibits SDMA and tumor growth in HCT116 MTAP-deleted tumor xenografts, compared to HCT116 MTAP-WT xenografts. Furthermore, treatment with AM-9747 inhibits the growth of multiple MTAP-deleted tumor xenograft models, including BXPC3 (PDAC) and DOHH2 (DLBCL). AM-9747 was profiled against a panel of over twenty PDX models, with greater than 50% tumor growth inhibition observed in the majority of PDX models harboring deletion of the MTAP gene. Our data with AM-9747 indicates that PRMT5 inhibitors that selectively target PRMT5 in cooperation with MTA may represent a novel and compelling therapeutic strategy for the treatment of MTAP-deleted cancers. Citation Format: Brian Belmontes, Antonia Policheni, Siyuan Liu, Katherine Slemmons, Jodi Moriguchi, Hayley Ma, Daniel Aiello, Yajing Yang, Mikkel Vestergaard, Sanne Cowland, Jan Anderson, Ian Sarvary, Nuria Tamayo, Liping Pettus, Susmith Mukund, Leszek Pope, Jennifer R. Allen, Sanne Glad, Matthew Bourbeau, Paul E. Hughes. The discovery and preclinical characterization of the MTA cooperative PRMT5 inhibitor AM-9747 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1807.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
陈一晨完成签到 ,获得积分10
2秒前
道元发布了新的文献求助10
2秒前
Ava应助终生科研徒刑采纳,获得10
3秒前
宇航员发布了新的文献求助100
4秒前
Ava应助骡子采纳,获得30
4秒前
吴晓敏完成签到 ,获得积分10
4秒前
5秒前
琉璃非离完成签到,获得积分10
5秒前
毒翼完成签到,获得积分10
6秒前
风中小懒虫完成签到,获得积分10
6秒前
科研通AI5应助七七采纳,获得10
8秒前
喵总发布了新的文献求助10
10秒前
苏钰完成签到,获得积分10
10秒前
隐形曼青应助103921wjk采纳,获得10
11秒前
喵总完成签到,获得积分10
15秒前
16秒前
17秒前
JamesPei应助浪迹天涯采纳,获得10
18秒前
vv完成签到,获得积分10
21秒前
103921wjk发布了新的文献求助10
21秒前
宇航员完成签到 ,获得积分10
22秒前
唐飒发布了新的文献求助10
22秒前
25秒前
曾经的臻发布了新的文献求助10
28秒前
飞翔的企鹅完成签到,获得积分10
29秒前
耍酷的醉蓝完成签到,获得积分10
31秒前
33秒前
37秒前
完美世界应助科研通管家采纳,获得10
37秒前
CipherSage应助科研通管家采纳,获得10
37秒前
昏睡的蟠桃应助科研通管家采纳,获得200
38秒前
38秒前
1z完成签到,获得积分10
38秒前
39秒前
俟天晴完成签到 ,获得积分10
39秒前
邰归应助公孙世往采纳,获得10
41秒前
41秒前
zhw发布了新的文献求助10
42秒前
mengzhao完成签到,获得积分10
43秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
Encyclopedia of Geology (2nd Edition) 2000
Периодизация спортивной тренировки. Общая теория и её практическое применение 310
Mixing the elements of mass customisation 300
the MD Anderson Surgical Oncology Manual, Seventh Edition 300
Nucleophilic substitution in azasydnone-modified dinitroanisoles 300
Platinum-group elements : mineralogy, geology, recovery 260
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3780394
求助须知:如何正确求助?哪些是违规求助? 3325811
关于积分的说明 10224284
捐赠科研通 3040879
什么是DOI,文献DOI怎么找? 1669109
邀请新用户注册赠送积分活动 799013
科研通“疑难数据库(出版商)”最低求助积分说明 758649